Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $18.89.

A number of research analysts have weighed in on the stock. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Wednesday, July 10th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th.

Teva Pharmaceutical Industries Stock Down 1.8 %

Shares of NYSE TEVA opened at $18.07 on Tuesday. The stock has a market cap of $20.47 billion, a P/E ratio of -44.07, a P/E/G ratio of 1.26 and a beta of 0.88. The firm has a 50 day moving average price of $17.59 and a 200 day moving average price of $15.99. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. Teva Pharmaceutical Industries has a 52-week low of $8.06 and a 52-week high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Analysts expect that Teva Pharmaceutical Industries will post 2.33 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lingotto Investment Management LLP increased its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after buying an additional 607,800 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Teva Pharmaceutical Industries by 13.4% in the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the period. Maple Rock Capital Partners Inc. increased its holdings in Teva Pharmaceutical Industries by 68.3% in the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after purchasing an additional 1,770,000 shares during the period. Truist Financial Corp increased its holdings in Teva Pharmaceutical Industries by 7.0% in the second quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock valued at $63,135,000 after purchasing an additional 254,483 shares during the period. Finally, Iron Triangle Partners LP increased its holdings in Teva Pharmaceutical Industries by 113.1% in the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after purchasing an additional 1,469,864 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.